Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 332

1.

Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.

Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP.

Atherosclerosis. 2019 Sep;288:85-93. doi: 10.1016/j.atherosclerosis.2019.07.008. Epub 2019 Jul 12.

2.

Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.

Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CP.

Atherosclerosis. 2019 Sep;288:194-202. doi: 10.1016/j.atherosclerosis.2019.06.896. Epub 2019 Jun 8.

3.

The role of genetics in cardiovascular risk reduction: Findings from a single lipid clinic and review of the literature.

Benes LB, Brummel K, Roth M, Shen L, Davidson MH.

Cardiovasc Revasc Med. 2019 May 8. pii: S1553-8389(19)30232-5. doi: 10.1016/j.carrev.2019.04.006. [Epub ahead of print]

PMID:
31153847
4.

Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials.

Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Eckel RH, Cannon CP, Lee LV, Bessac L, Pordy R, Letierce A, Ray KK.

J Am Heart Assoc. 2018 Sep 18;7(18):e009221. doi: 10.1161/JAHA.118.009221.

5.

How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention.

Benes LB, Brandt DJ, Brandt EJ, Davidson MH.

Curr Cardiol Rep. 2018 Oct 17;20(12):138. doi: 10.1007/s11886-018-1079-3. Review.

PMID:
30328514
6.

PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety.

Roth EM, Davidson MH.

Rev Cardiovasc Med. 2018;19(S1):S31-S46. Review.

PMID:
30207556
7.

Can We Cure Atherosclerosis?

Robinson JG, Davidson MH.

Rev Cardiovasc Med. 2018;19(S1):S20-S24. Review.

PMID:
30207554
8.

ω-6 Polyunsaturated Fatty Acids and Cardiometabolic Health: Current Evidence, Controversies, and Research Gaps.

Maki KC, Eren F, Cassens ME, Dicklin MR, Davidson MH.

Adv Nutr. 2018 Nov 1;9(6):688-700. doi: 10.1093/advances/nmy038.

9.

Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.

Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Pedersen TR, Ridker PM, Ray K, Karlson BW, Lundström T, Wolski K, Nissen SE.

Clin Cardiol. 2018 Oct;41(10):1281-1288. doi: 10.1002/clc.23055. Epub 2018 Sep 28. Review.

10.

Clinical trials.

Davidson MH.

Curr Opin Lipidol. 2018 Jun;29(3):277-278. doi: 10.1097/MOL.0000000000000512. No abstract available.

PMID:
29715246
11.

Evolution of Omega-3 Fatty Acid Therapy and Current and Future Role in the Management of Dyslipidemia.

Benes LB, Bassi NS, Kalot MA, Davidson MH.

Cardiol Clin. 2018 May;36(2):277-285. doi: 10.1016/j.ccl.2017.12.009. Epub 2018 Feb 21. Review.

PMID:
29609757
12.

Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).

McCullough PA, Ballantyne CM, Sanganalmath SK, Langslet G, Baum SJ, Shah PK, Koren A, Mandel J, Davidson MH.

Am J Cardiol. 2018 Apr 15;121(8):940-948. doi: 10.1016/j.amjcard.2017.12.040. Epub 2018 Feb 2.

13.

Cardiorenal Safety of OTC Analgesics.

White WB, Kloner RA, Angiolillo DJ, Davidson MH.

J Cardiovasc Pharmacol Ther. 2018 Mar;23(2):103-118. doi: 10.1177/1074248417751070. Review.

14.

Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-C.

Davidson MH.

Eur Heart J. 2018 Feb 14;39(7):620-622. doi: 10.1093/eurheartj/ehx741. No abstract available.

PMID:
29342252
15.

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial.

Stroes ESG, Susekov AV, de Bruin TWA, Kvarnström M, Yang H, Davidson MH.

J Clin Lipidol. 2018 Mar - Apr;12(2):321-330. doi: 10.1016/j.jacl.2017.10.012. Epub 2017 Oct 27.

16.

Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia.

Benes LB, Bassi NS, Davidson MH.

Vasc Health Risk Manag. 2016 Dec 12;12:481-490. doi: 10.2147/VHRM.S58149. eCollection 2016. Review.

17.

Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©.

Jacobson TA, Edelman SV, Galipeau N, Shields AL, Mallya UG, Koren A, Davidson MH.

Patient. 2017 Jun;10(3):321-334. doi: 10.1007/s40271-016-0211-y.

18.

Intensive statin therapy in India: Demonstrating efficacy and safety.

Davidson MH.

Indian Heart J. 2016 Nov - Dec;68(6):756-757. doi: 10.1016/j.ihj.2016.09.006. Epub 2016 Sep 20. No abstract available.

19.

The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.

Morton AM, Furtado JD, Lee J, Amerine W, Davidson MH, Sacks FM.

J Clin Lipidol. 2016 Nov - Dec;10(6):1442-1451.e4. doi: 10.1016/j.jacl.2016.09.005. Epub 2016 Sep 13.

PMID:
27919362
20.

The future of n-3 polyunsaturated fatty acid therapy.

Davidson MH, Benes LB.

Curr Opin Lipidol. 2016 Dec;27(6):570-578. Review.

PMID:
27798489

Supplemental Content

Loading ...
Support Center